Option chain shows key data for IO Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IO Biotech.

IO Biotech (NASDAQ:IOBT) Stock, Option Chain

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

movers image

AGFY

EFSH

GLMD

HCTI

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

ADAG

ATPC

DRMA

EGIO

ENTO

ITOS

LDTC

NCNA

PPBT

PTIX

SQFT

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

IO Biotech Inc

Health Care

Financing

Press Releases

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech Reports 2024 Business Highlights

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

General

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Agenus

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

Cabaletta Bio

Cibus

CytomX Therapeutics

Citius Oncology

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MediciNova

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pyxis Oncology

Repare Therapeutics

Skye Bioscience

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Exicure

HC Wainwright & Co.

Morgan Stanley

Piper Sandler

Comments

IO Biotech

IO Biotech (IOBT) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell